Blue Water Vaccines

Blue Water Vaccines, Inc. is a biotechnology company that focuses on the research and development of transformational vaccines to prevent infectious diseases worldwide. Its vaccine platform has molecular properties that enable delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. The company's influenza vaccine program uses proprietary technology to identify specific epitopes, or proteins, with cross-reactive properties that enable the potential development of a universal flu vaccine. Its pipeline includes novel vaccine candidates licensed from research institutions and seeks to develop vaccines that provide long-lasting immunity to harmful viral and bacterial pathogens that cause infections in patient populations with high unmet needs. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.

CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research Agreement (the “Agreement”) with The University of Texas Health Science Center at San Antonio (“UT Health Science Center San Antonio”) to fund a non-human primate (“NHP”) study to evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine.

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress. Blue Water Vaccines is a preclinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (“AOM”) and pneumonia from Streptococcus pneumoniae colonization, influenza, norovirus, rotavirus, monkeypox, Marburg virus disease and Chlamydia.

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Amesite Operating

Ideanomics Inc

Here's some tips on how to trade penny stocks online The post How to Trade Penny Stocks Online: Short Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Trade Penny Stocks Online: Short Guide

GlycoMimetics

Iris Energy Ltd

Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?

Penny Stocks To Buy After CPI Report? 3 To Watch Today

CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development.

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Timothy Ramdeen, seasoned public market and private equity investment leader, to its board of directors.

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

CINCINNATI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at the Biotech Showcase 2023 in San Francisco, California, happening during the 41st Annual J.P. Morgan Healthcare Conference. During the presentation, management will provide a corporate overview, recent milestones and execution, and company pipeline updates.

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

CINCINNATI, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage since going public in February 2022 with the initial recommendations as “buy” from both Maxim Group LLC (“Maxim”) and H.C. Wainwright & Co. (“H.C. Wainwright”) at price targets of $4 and $7, respectively.

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the Company will host an online Key Opinion Leader (“KOL”) event on Wednesday, December 7, 2022 from 12 p.m. – 2 p.m. EST.

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022. Dr. Fattom will present an overview and current progress of BWV-201, a live attenuated, intranasally delivered, serotype independent Streptococcus pneumoniae vaccine candidate for the prevention of acute otitis media (“AOM”), pneumococcal pneumonia, and invasive pneumococcal disease.

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress

CINCINNATI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent business developments and progress. Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (AOM) and pneumonia from Streptococcus pneumoniae colonization, influenza, norovirus, and rotavirus.

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced plans to investigate the ability of BWV-201, a Streptococcus pneumoniae vaccine candidate for acute otitis media (“AOM”) prevention, to also protect against non-invasive pneumococcal pneumonia at the World Vaccine Congress in Barcelona.

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona

CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company will host a roundtable discussion and present at the World Vaccine Congress Europe 2022 in Barcelona, Spain.

Blue Water Vaccines to Present at World Vaccine Congress Europe 2022

CINCINNATI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced an update to its presentation at the H.C. Wainwright 24th Annual Global Investment Conference. Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines, will present a company overview in person, with an option to view the presentation online via webcast link, on Monday, September 12, 2022 at 9am EDT.

Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright's 24th Annual Global Investment Conference in New York, NY

American Virtual Cloud Technologies

ObsEva

Here's what you need to know about trading penny stocks on August 30th The post Hot Penny Stocks For Your Buy List in September? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For Your Buy List in September? 3 to Watch

CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that scientists from its research partner, The University of Oxford, will present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom on Monday, September 5th, 2022.

Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom

CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Simon Tarsh, seasoned financial consultant with experience in the life science industry, to its board of directors at BWV's annual meeting.

Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors

Source: angellodeco / Shutterstock.com Blue Water Vaccines (NASDAQ: BWV ) stock is rocketing higher on Wednesday after the company announced it will explore the possibility of making a monkeypox vaccine. According to a press release from the company, it intends to use its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for this.

BWV Stock Soars as Blue Water Vaccines Explores Monkeypox Vaccine

CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform.

Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Ayala Pharmaceuticals

E-Home Household Service Holdings Ltd

Ameri Holdings

Koss

Stronghold Digital Mining

SIGA Technologies

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.

7 Short-Squeeze Stocks to Put on Your Must-Watch List

Genius Group Ltd

Golden Sun Education Group Ltd

AMTD Digital

JE Cleantech Holdings Ltd

Magic Empire Global Ltd

Ostin Technology Group Co Ltd

Yoshitsu Co Ltd

Tenon Medical Inc

Visionary Education Technology Holdings Group Inc

WeTrade Group Inc

So far in 2022, IPO activity has been dominated by small, volatile issuers. Of the 19 IPOs with 100%+ pops, 17 have traded down from the first-day close, and 11 trade below issue.

2022 IPOs With The Largest First-Day Pops Are Now Some Of The Worst Performers

CINCINNATI, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent business developments and progress. Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (AOM) from Streptococcus pneumoniae colonization, influenza, norovirus, and rotavirus.

Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights

CINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the closing of its previously announced private placement of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) to several healthcare-focused institutional investors, that was priced at-the-market under Nasdaq rules. The Company also issued to investors unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 4,972,428 shares of common stock. The purchase price for one share of common stock (or common stock equivalent) and one investment option was $2.715. The investment options have an exercise price of $2.546 per share, are exercisable immediately upon issuance, and have a term equal to five years.

Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Source: shutterstock.com/PhotobyTawat Blue Water Vaccines (NASDAQ: BWV ) stock is jumping more than 50% today despite having no news to offer. Based in Cincinnati, the company works on vaccines for flu and pneumonia.

News for Blue Water Vaccines Stock (BWV)